ASX - By Stock
|
TYP |
Re:
Where to from here
|
|
Al.
|
104 |
32K |
5 |
04/03/22 |
04/03/22 |
ASX - By Stock
|
104
|
32K
|
5
|
|
ASX - By Stock
|
TYP |
Re:
Where to from here
|
|
Al.
|
104 |
32K |
4 |
25/02/22 |
25/02/22 |
ASX - By Stock
|
104
|
32K
|
4
|
|
ASX - By Stock
|
OPT |
Re:
Ann: Opthea announces establishment of ATM Equity Program
|
|
Al.
|
17 |
7.7K |
1 |
02/02/22 |
02/02/22 |
ASX - By Stock
|
17
|
7.7K
|
1
|
|
ASX - By Stock
|
LBT |
Re:
Ann: LBT to Obtain Full Ownership of CCS Joint Venture
|
|
Al.
|
29 |
11K |
2 |
29/12/21 |
29/12/21 |
ASX - By Stock
|
29
|
11K
|
2
|
|
ASX - By Stock
|
TYP |
Re:
Codiak
|
|
Al.
|
4 |
1.2K |
2 |
29/12/21 |
29/12/21 |
ASX - By Stock
|
4
|
1.2K
|
2
|
|
ASX - By Stock
|
TYP |
Re:
Codiak
|
|
Al.
|
4 |
1.2K |
4 |
29/12/21 |
29/12/21 |
ASX - By Stock
|
4
|
1.2K
|
4
|
|
ASX - By Stock
|
TYP |
Re:
Codiak
|
|
Al.
|
4 |
1.2K |
13 |
29/12/21 |
29/12/21 |
ASX - By Stock
|
4
|
1.2K
|
13
|
|
ASX - By Stock
|
OSL |
Re:
Ann: PanCO Clinical Study on OncoSil Published in ESMO Open
|
|
Al.
|
29 |
15K |
5 |
24/12/21 |
24/12/21 |
ASX - By Stock
|
29
|
15K
|
5
|
|
ASX - By Stock
|
GSS |
Re:
News: GSS Genetic Signatures Expects Sales Of At Least A$21M For Half Year
|
|
Al.
|
30 |
9.1K |
4 |
23/12/21 |
23/12/21 |
ASX - By Stock
|
30
|
9.1K
|
4
|
|
ASX - By Stock
|
TYP |
Re:
Ann: Exopharm Gains US Patent for LEAP Technology
|
|
Al.
|
24 |
11K |
11 |
23/12/21 |
23/12/21 |
ASX - By Stock
|
24
|
11K
|
11
|
|
ASX - By Stock
|
GSS |
Re:
News: GSS Genetic Signatures Expects Sales Of At Least A$21M For Half Year
|
|
Al.
|
30 |
9.1K |
1 |
22/12/21 |
22/12/21 |
ASX - By Stock
|
30
|
9.1K
|
1
|
|
ASX - By Stock
|
RHY |
Re:
Ann: CE Mark Granted for ColoSTAT
|
|
Al.
|
66 |
18K |
6 |
01/12/21 |
01/12/21 |
ASX - By Stock
|
66
|
18K
|
6
|
|
ASX - By Stock
|
RHY |
Re:
Ann: CE Mark Granted for ColoSTAT
|
|
Al.
|
66 |
18K |
7 |
01/12/21 |
01/12/21 |
ASX - By Stock
|
66
|
18K
|
7
|
|
ASX - By Stock
|
WSI |
Re:
Ann: Alltype secures $12M Lynas contract, WestStar raises $3.5M
|
|
Al.
|
36 |
8.5K |
6 |
12/11/21 |
12/11/21 |
ASX - By Stock
|
36
|
8.5K
|
6
|
|
ASX - By Stock
|
TYP |
Re:
Ann: Exopharm LEAP Technology - Second Commercial Collaboration
|
|
Al.
|
76 |
23K |
18 |
08/09/21 |
08/09/21 |
ASX - By Stock
|
76
|
23K
|
18
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: BARD1 Collaborator Uni of QLD Announces Ovarian Cancer Data
|
|
Al.
|
21 |
9.5K |
2 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
21
|
9.5K
|
2
|
|
ASX - By Stock
|
WSI |
Re:
Ann: Trading Halt
|
|
Al.
|
40 |
13K |
1 |
21/07/21 |
21/07/21 |
ASX - By Stock
|
40
|
13K
|
1
|
|
ASX - By Stock
|
LVT |
Re:
Ann: LVT secures deal with Fortune Global 100 company Nestle
|
|
Al.
|
108 |
60K |
19 |
12/07/21 |
12/07/21 |
ASX - By Stock
|
108
|
60K
|
19
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: BARD1 Investor Presentation
|
|
Al.
|
29 |
12K |
30 |
07/07/21 |
07/07/21 |
ASX - By Stock
|
29
|
12K
|
30
|
|
ASX - By Stock
|
DTS |
Re:
Ann: Dragontail Enters Into Scheme Implementation Deed
|
|
Al.
|
114 |
27K |
1 |
29/05/21 |
29/05/21 |
ASX - By Stock
|
114
|
27K
|
1
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test
|
|
Al.
|
82 |
32K |
11 |
25/05/21 |
25/05/21 |
ASX - By Stock
|
82
|
32K
|
11
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test
|
|
Al.
|
82 |
32K |
4 |
25/05/21 |
25/05/21 |
ASX - By Stock
|
82
|
32K
|
4
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test
|
|
Al.
|
82 |
32K |
5 |
25/05/21 |
25/05/21 |
ASX - By Stock
|
82
|
32K
|
5
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: BARD1 Launches its RUO EXO-NET Product
|
|
Al.
|
53 |
23K |
5 |
21/05/21 |
21/05/21 |
ASX - By Stock
|
53
|
23K
|
5
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: Positive Results from the BARD1 Autoantibody Assay
|
|
Al.
|
69 |
19K |
10 |
29/04/21 |
29/04/21 |
ASX - By Stock
|
69
|
19K
|
10
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: Positive Results from the BARD1 Autoantibody Assay
|
|
Al.
|
69 |
19K |
10 |
29/04/21 |
29/04/21 |
ASX - By Stock
|
69
|
19K
|
10
|
|
ASX - By Stock
|
APC |
Re:
Ann: Massive Nickel Sulphide Targets Identified at Laverton Downs
|
|
Al.
|
29 |
11K |
3 |
09/04/21 |
09/04/21 |
ASX - By Stock
|
29
|
11K
|
3
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: Commencement of Legal Proceedings Against BARD1
|
|
Al.
|
133 |
54K |
2 |
30/03/21 |
30/03/21 |
ASX - By Stock
|
133
|
54K
|
2
|
|
ASX - By Stock
|
IIQ |
Re:
SP targets
|
|
Al.
|
48 |
21K |
20 |
23/03/21 |
23/03/21 |
ASX - By Stock
|
48
|
21K
|
20
|
|
ASX - By Stock
|
IIQ |
Re:
Is this the next CSL?
|
|
Al.
|
13 |
6.0K |
2 |
19/02/21 |
19/02/21 |
ASX - By Stock
|
13
|
6.0K
|
2
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: Becoming a substantial holder
|
|
Al.
|
45 |
15K |
8 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
45
|
15K
|
8
|
|
ASX - By Stock
|
IIQ |
Re:
Chart Thread
|
|
Al.
|
1.4K |
562K |
7 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
1.4K
|
562K
|
7
|
|
ASX - By Stock
|
IIQ |
Re:
Chart Thread
|
|
Al.
|
1.4K |
562K |
7 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
1.4K
|
562K
|
7
|
|
ASX - By Stock
|
IIQ |
Re:
Chart Thread
|
|
Al.
|
1.4K |
562K |
8 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
1.4K
|
562K
|
8
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: Outstanding SubB2M Ovarian Cancer Test Data
|
|
Al.
|
532 |
176K |
16 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
532
|
176K
|
16
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: Outstanding SubB2M Ovarian Cancer Test Data
|
|
Al.
|
532 |
176K |
7 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
532
|
176K
|
7
|
|
ASX - By Stock
|
IIQ |
Re:
Chart Thread
|
|
Al.
|
1.4K |
562K |
4 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
1.4K
|
562K
|
4
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: Outstanding SubB2M Ovarian Cancer Test Data
|
|
Al.
|
532 |
176K |
13 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
532
|
176K
|
13
|
|
ASX - By Stock
|
IIQ |
Re:
Bd1 bang
|
|
Al.
|
23 |
7.4K |
1 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
23
|
7.4K
|
1
|
|
ASX - By Stock
|
TYP |
Re:
Value in new medicines and longer strides
|
|
Al.
|
112 |
39K |
3 |
07/02/21 |
07/02/21 |
ASX - By Stock
|
112
|
39K
|
3
|
|
ASX - By Stock
|
TYP |
Re:
Value in new medicines and longer strides
|
|
Al.
|
112 |
39K |
0 |
07/02/21 |
07/02/21 |
ASX - By Stock
|
112
|
39K
|
0
|
|
ASX - By Stock
|
TYP |
Re:
Value in new medicines and longer strides
|
|
Al.
|
112 |
39K |
5 |
07/02/21 |
07/02/21 |
ASX - By Stock
|
112
|
39K
|
5
|
|
ASX - By Stock
|
RNT |
Re:
Ann: Share Placement to Strategic Investor
|
|
Al.
|
257 |
82K |
4 |
02/02/21 |
02/02/21 |
ASX - By Stock
|
257
|
82K
|
4
|
|
ASX - By Stock
|
RNT |
Re:
Ann: Share Placement to Strategic Investor
|
|
Al.
|
257 |
82K |
2 |
02/02/21 |
02/02/21 |
ASX - By Stock
|
257
|
82K
|
2
|
|
ASX - By Stock
|
RNT |
Re:
Next stop
|
|
Al.
|
12 |
6.2K |
6 |
02/02/21 |
02/02/21 |
ASX - By Stock
|
12
|
6.2K
|
6
|
|
ASX - By Stock
|
RNT |
Re:
Ann: Share Placement to Strategic Investor
|
|
Al.
|
257 |
82K |
8 |
02/02/21 |
02/02/21 |
ASX - By Stock
|
257
|
82K
|
8
|
|
ASX - By Stock
|
RNT |
Re:
Ann: Share Placement to Strategic Investor
|
|
Al.
|
257 |
82K |
4 |
02/02/21 |
02/02/21 |
ASX - By Stock
|
257
|
82K
|
4
|
|
ASX - By Stock
|
TYP |
Re:
Ann: Quarterly Report and Appendix 4C
|
|
Al.
|
35 |
9.9K |
1 |
29/01/21 |
29/01/21 |
ASX - By Stock
|
35
|
9.9K
|
1
|
|
ASX - By Stock
|
TYP |
Re:
Ann: Quarterly Report and Appendix 4C
|
|
Al.
|
35 |
9.9K |
1 |
29/01/21 |
29/01/21 |
ASX - By Stock
|
35
|
9.9K
|
1
|
|
ASX - By Stock
|
MNS |
Re:
$1 Party
|
|
Al.
|
132 |
57K |
2 |
29/01/21 |
29/01/21 |
ASX - By Stock
|
132
|
57K
|
2
|
|